December 17, 2016Clinical EndocrinologyOpen Access

Neonatal 17‐hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening

View Full Paper

Ask AI

Bookmark

Abstract

Neonatal 17-hydroxyprogesterone levels adjusted to sample collection age and birthweight reduced the FPR, and the use of N17OHP values based upon the 99·8th percentile improved the NBS efficacy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hayashi et al. (2016) studied this question.

synapsesocial.com/papers/69d89ce0a5ecc596b5d17e27 https://doi.org/10.1111/cen.13292

View Full Paper

Ask AI

Bookmark

Abstract

Neonatal 17-hydroxyprogesterone levels adjusted to sample collection age and birthweight reduced the FPR, and the use of N17OHP values based upon the 99·8th percentile improved the NBS efficacy.

Neonatal 17‐hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening

Abstract

Discussion

Cite This Study

Neonatal 17‐hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screening

Abstract

Discussion

Cite This Study

Keep reading

Keep reading